NovaBay Pharmaceuticals, Inc.
NBY
$1.03
$0.4371.67%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.74M | 7.12M | 9.75M | 9.56M | 9.61M |
| Total Other Revenue | 14.00K | 27.00K | 34.00K | 9.00K | 2.00K |
| Total Revenue | 4.75M | 7.15M | 9.78M | 9.57M | 9.61M |
| Cost of Revenue | 1.66M | 1.66M | 1.66M | 1.87M | 1.84M |
| Gross Profit | 3.10M | 3.10M | 3.10M | 2.68M | 2.75M |
| SG&A Expenses | 10.02M | 9.75M | 9.34M | 8.65M | 8.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.69M | 11.42M | 11.01M | 10.52M | 10.20M |
| Operating Income | -6.94M | -6.67M | -6.26M | -5.98M | -5.61M |
| Income Before Tax | -7.83M | -8.01M | -7.61M | -8.01M | -8.15M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.83 | -8.01 | -7.61 | -8.01 | -8.15 |
| Earnings from Discontinued Operations | 11.15M | 11.68M | 386.00K | -2.11M | -2.52M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.32M | 3.66M | -7.22M | -10.12M | -10.66M |
| EBIT | -6.94M | -6.67M | -6.26M | -5.98M | -5.61M |
| EBITDA | -6.92M | -6.64M | -6.22M | -5.94M | -5.57M |
| EPS Basic | 0.37 | -0.68 | -32.07 | -78.45 | -90.96 |
| Normalized Basic EPS | -0.84 | -1.75 | -17.00 | -22.35 | -28.45 |
| EPS Diluted | 0.36 | -0.68 | -32.07 | -78.45 | -90.96 |
| Normalized Diluted EPS | -0.83 | -1.74 | -17.00 | -22.35 | -28.45 |
| Average Basic Shares Outstanding | 22.83M | 18.17M | 12.98M | 5.18M | 1.61M |
| Average Diluted Shares Outstanding | 22.94M | 18.28M | 12.98M | 5.18M | 1.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |